Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
|Articles|February 13, 2006
NCPA calls R.Ph.s to action
Pharmacists in all settings must take personal action to defend their profession against outsiders who wish to marginalize them as frontline healthcare providers, according to NCPA. Warning that 2006 is a "now or never" year, NCPA pointed to Medicare Part D, severe cuts to Medicaid reimbursement, and growing mandatory mail order as examples of efforts to undermine traditional community pharmacy practice.
Advertisement
Advertisement
Related to this article
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5